Mechanisms Underlying Cardiovascular Consequences Associated With COVID-19 and Long COVID
Purpose
AIM 1. Characterize cardiovascular phenotypes of long COVID by cardiopulmonary, meta-bolic, and cardiac mechanical/physiological responses to exercise and microvascular vasomotor function. AIM 2. Identify intercellular signaling between immune cells and cardiac cells associated with microvascular phenotypes of long COVID.
Condition
- COVID-19
Eligibility
- Eligible Ages
- Between 19 Years and 74 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Age > 18, < 75 yrs - History of lab-confirmed COVID - Symptomatic at >12 wks post-acute COVID (cases) - Recovered by 8wks post-acute COVID (controls)
Exclusion Criteria
- Any history of critical illness - Chronic kidney disease, Stage >4 - Pre-COVID: HFrEF, CABG, arrhythmia; pulmonary hypertension, pulmonary embolus, interstitial lung disease (ILD), O2 dependence; dementia, stroke, autonomic dysfunction; coagulopathy - Post-COVID: ILD, O2 dependence
Study Design
- Phase
- Study Type
- Observational
- Observational Model
- Case-Control
- Time Perspective
- Prospective
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
COVID patients | Patients with long COVID-19 and experiencing cardiovascular symptoms at 24 weeks post-acute illness or post-COVID without cardiovascular symptoms by 8 weeks after illness. |
Recruiting Locations
More Details
- NCT ID
- NCT06427512
- Status
- Withdrawn
- Sponsor
- Columbia University
Detailed Description
As many as 40-60% of patients who recovered from mild or moderate acute COVID have reported what is now called long COVID - multiple, persistent or recurrent symptoms lasting 6-9 months (or longer) following initial illness.1-4 Fatigue, dyspnea, and chest pain are the most common symptoms. Others include palpitations, lightheadedness, and syncope. All these cardiovascular symptoms can be debilitating, resulting in worse quality of life and morbidity.5, 6 Treatment options are limited.